Psychedelic Medicine Media ArticlesExcerpts of Key Psychedelic Medicine Media Articles in Major Media
Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
Psychedelics startups don't just want to just reinvent mental health. They also want to reinvent capitalism. And judging by the news coming out of last week's "Horizons: Perspectives on Psychedelics" conference in Manhattan, they're having some early success. Stephen Jurvetson, co-founder of Future Ventures and a board member at SpaceX, told me ... that he's a true believer in the industry's mission to fix the state of mental-health care. He decided last week to carve up his own estate by giving around half of his net worth to fund psychedelic science. Organizations like the public-benefit corporation of Multidisciplinary Association for Psychedelics Studies, or MAPS, and the Psychedelic Science Funders Collaborative, a nonprofit organization, have both accepted charitable donations but fund research that could lead to blockbuster drugs. Psychedelics startups do need funding, and badly. Like biotech, it's a high-risk industry with expensive clinical trials and regulatory uncertainty. And patents, a traditional financial engine for biotech, are harder to win for plants that have been around for centuries, or molecules that have already made the rounds as street drugs. MAPS also made a major announcement: The New York-based venture capital fund Vine Ventures has created a $70 million special purpose vehicle to fund its Phase 3 clinical trials on post-traumatic stress disorder and MDMA. The novel funding method ... will help keep MAPS a nonprofit while letting it retain control of its intellectual property.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
Legal psychedelic medicine is poised to soon disrupt the multibillion-dollar mental health field. Treatments being trialed today in clinical settings using substances like psilocybin-containing mushrooms will soon offer legal alternatives to the more than 50 percent of patients receiving therapy for major depressive disorder (MDD) who do not respond to approved depression medications. The creation of new effective therapies will likely put pressure on healthcare providers to examine the upside of psychedelic therapies and how such treatments will inevitably affect their bottom line. While these therapies will not be a cure-all for everyone, over the next three to five years an expanding number of psychedelic treatments will produce alternatives for the many patients who find no relief from FDA-approved, first-line therapeutics like selective serotonin reuptake inhibitors (SSRIs). Since legalizing the use of psilocybin-containing magic mushrooms in 2020 through a ballot measure, Oregon is now in the process of creating an intricate statewide system for qualified caregivers to deliver psilocybin treatments in therapeutic settings. Sessions using psilocybin can last over six hours, which does not include vital therapy before and after treatments. MDMA-assisted therapy for severe post-traumatic stress disorder (PTSD), which is very close to being an FDA-approved therapy, will likewise require significant clinician involvement before, during and after a session.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
Jose Martinez, a former Army gunner whose right arm and both legs were blown off by a roadside bomb in Afghanistan, has a new calling: He's become one of the most effective lobbyists in a campaign to legalize the therapeutic use of psychedelic drugs across the country. On a Zoom call ... with Connie Leyva, a Democratic legislator in California who has long opposed relaxing drug laws, Mr. Martinez told her how psilocybin, the psychoactive ingredient in "magic" mushrooms, had helped to finally quell the physical pain and suicidal thoughts that had tormented him. Ms. Leyva says she changed her mind even before the call ended, and she later voted yes on the bill, which is expected to become law early next year. In the two years since Oregon, Washington, D.C., and a half-dozen municipalities decriminalized psilocybin, vets have become leading advocates in the drive to legalize psychedelic medicine, which they credit with helping ease the post-traumatic stress, anxiety and depression that are often tied to their experiences in the military. The campaign has been propelled by the epidemic of suicides among veterans ... but also by the national reckoning over the mass incarceration of people on drug charges. More than 30,000 service members have taken their own lives in the years since Sept. 11 – four times the number of those who died on the battlefield. "I will not be told no on something that prevents human beings from killing themselves," Mr. Martinez said.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage." Then, all at once, the soul-crushing, depressive fog started to lift, and the most meaningful experience of his life began. The turning point for Presley came as he lay on a psychiatrist's couch at Johns Hopkins University. He had consumed a large dose of psilocybin, the active ingredient in what's more commonly known as magic mushrooms, and entered a state that could best be described as lucid dreaming. Visions of family and childhood triggered overwhelming and long-lost feelings of love, he says. Presley was one of 24 volunteers taking part in a small study aimed at evaluating the effectiveness of a combination of psychotherapy and this powerful mind-altering drug to treat depression–an approach that, should it win approval, could be the biggest advance in mental health since Prozac in the 1990s. Depression ... affects 320 million people around the world. Roughly one-third of those who seek treatment won't respond to verbal or conventional drug therapies. Magic-mushroom therapy is offering some hope for these hopeless cases. In the Hopkins study, published last year in JAMA Psychiatry, the therapy was four times more effective than traditional antidepressants. Two-thirds of participants showed a more-than 50-percent reduction in depression symptoms after one week; a month later, more than half were considered in remission, meaning they no longer qualified as being depressed.
Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
In the last 10 years, psychedelic drugs like LSD, magic mushrooms, DMT, a host of "plant medicines" – including ayahuasca, iboga, salvia, peyote – and related compounds like MDMA and ketamine have begun to lose much of their 1960s-driven stigma. Promising clinical trials suggest that psychedelics may prove game-changing treatments for depression, PTSD and addiction. The response from the psychiatric community ... has been largely open-armed. The drugs may well mark the field's first paradigm shift since SSRIs in the 1980s. In 2017, for example, the US Food and Drug Administration designated MDMA a "breakthrough therapy", which meant it would be fast-tracked through to the second stage of Phase-3 trials. Psychedelics remain Schedule-1 drugs federally in the US and Class-A in the UK, but rules are relaxing. This wave of psychedelic enthusiasm in psychiatry isn't the first. They were originally heralded as wonder drugs in the 1950s. Across some 6,000 studies on over 40,000 patients, psychedelics were tried as experimental treatments for an extraordinary range of conditions: alcoholism, depression, schizophrenia, criminal recidivism, childhood autism. And the results were promising. From as little as a single LSD session, studies suggested that the drug relieved problem drinking for 59% of alcoholic participants. Experimenting with lower, so-called "psycholytic" doses, many therapists were amazed by LSD's power as an adjunct to talking therapy.
Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Fungi have been around for billions of years, setting the stage for humanity by supporting, carrying and converting life. But for complex political reasons, these organisms are still shrouded in mystery. One man, however, is determined to lift the veil on the magical world of mushrooms. Enter Stamets, a bespectacled author and researcher whose mission to decode nature's hidden language and explore "altered states of consciousness" is chronicled in the documentary "Fantastic Fungi," which was recently made available to stream on Netflix. While the film aims to destigmatize hallucinogenic mushrooms, it also demonstrates why we should legitimize the studies of all mushrooms. Contemporary experts in neurology, psychiatry and biology in the film show that fungal genomes can solve a host of mental, physical and environmental problems. From healing bacterial infections to cleaning petroleum spills, fungi possess unique, almost godlike properties that are otherwise unseen in nature. For instance, lion's mane, an edible white mushroom that tastes like lobster, stimulates nerves in order to grow, suggesting that it could potentially cure degenerative diseases like Alzheimer's. Ultimately, when Stamets discusses altered states of consciousness, it's ... about accepting a different state of being. For some people – especially those who live in pain – the film posits that mushrooms can be the answer they've been looking for.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Psychedelic drugs are substances that alter perception and mood and affect a number of cognitive processes. The classic psychedelics include MDMA aka "ecstasy" or "molly," LSD, psilocybin or "mushrooms," ayahuasca and ibogaine. Used in conjunction with therapists, research has shown that psychedelics can help treat historically difficult-to-treat conditions by essentially "reshaping" the way "parts of the brain talk to each other," says Jennifer Mitchell, a neuroscientist. "Psychedelics allow for processing in a way that enables subjects to let go of things that had previously plagued them," she says. As Mitchell explains it, when people are young, their brains go through critical periods of learning and development that then become closed off as they age. Researchers believe that psychedelics "open those closed critical periods for just a tiny window of time," she says. "When that critical period is open again, you want to make the most of it, and make that potential change as positive as possible," she says. With psilocybin, for instance, it is believed the drug boosts connectivity in the brain and increases "neuroplastic states," which are the brain's ability to reorganize and adapt, says Dr. Stephen Ross ... who has been conducting clinical trials on psilocybin-assisted therapy for the past 16 years. MDMA-assisted therapy could be approved by the FDA for medical use as early as 2023, while other psychedelics, notably psilocybin, are waiting in the wings for their turn to be evaluated for medical purposes.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
In the past two years, a new drug policy reform movement called Decriminalize Nature has persuaded local governments in a half dozen municipalities, including Washington, D.C., to decriminalize "plant medicines" such as psilocybin, ayahuasca, iboga and the cactuses that produce mescaline. Last month, the California State Senate passed a bill that would make legal the personal possession, use and "social sharing" of psychedelics, including LSD and MDMA, a.k.a. Ecstasy or Molly. Political opposition to all these measures has been notably thin. Neither party, it seems, has the stomach for persisting in a war that has achieved so little while doing so much damage, especially to communities of color and our civil liberties. But while we can now begin to glimpse an end to the drug war, it is much harder to envision what the drug peace will look like. How will we fold these powerful substances into our society and our lives so as to minimize their risks and use them most constructively? In the case of psychedelics, decriminalizing these powerful compounds is only the first step in a process of figuring out how best to safely weave their use into our society. The main model we have for resocializing a formerly illicit drug is the legalization of cannabis, now the new normal in 18 states. The use of psychedelics by Indigenous peoples ... suggests a model we would do well to keep in mind as we figure out how best to handle these substances.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind altering drugs from reliable major media sources.
MDMA - most commonly known as a party drug - could be more effective than therapy alone at treating post-traumatic stress disorder (PTSD). The results of a keenly-awaited trial suggest two-thirds of people no longer qualified for a PTSD diagnosis after treatment. The study represents a significant step towards approval of the drug in the US. PTSD can be the result of a very distressing or frightening event, or longer-term series of experiences. That might include accidents, abuse, rape, combat or illness. And it can be very difficult to treat. This trial, run by US charity the Multidisciplinary Association for Psychedelic Studies (Maps), found 88% of people had a "meaningful reduction in symptoms" and 67% no longer qualified for a PTSD diagnosis at all after 18 weeks and three sessions of MDMA-assisted therapy. Talking therapy alone led to a significant improvement in 60%, and remission in 32% of people. The participants in the study, which was published in the journal Nature, had suffered from PTSD for an average of 14 years. MDMA appears to work in part by calming the amygdala. In people with PTSD and anxiety disorders, this part of the brain can overreact, sounding the alarm over seemingly small events. When we are babies, and again during adolescence, we experience periods where our brains are very pliable. The scientists involved in the study speculate that psychedelics and similar-acting drugs like MDMA might allow a "reopening" of this critical window of brain development.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
It's been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds. Dr. Doblin's quest to win mainstream acceptance of psychedelics took a significant leap forward ... when the journal Nature Medicine published the results of his lab's study on MDMA, the club drug popularly known as Ecstasy and Molly. The study, the first Phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder. The results, coming weeks after a New England Journal of Medicine study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically – for MDMA as soon as 2023, followed by psilocybin a year or two later. Last year, Oregon became the first state to legalize the therapeutic use of psilocybin. Denver, Oakland, Calif., and Washington, D.C., have decriminalized the drug, and several states, including California, are mulling similar legislation. Though the drugs remain illegal under federal law, the Justice Department has so far taken a hands-off approach to enforcement.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy. Of the 90 people who took part in the new study, which is expected to be published later this month in Nature Medicine, those who received MDMA during therapy experienced a significantly greater reduction in the severity of their symptoms compared with those who received therapy and an inactive placebo. Two months after treatment, 67 percent of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32 percent in the placebo group. MDMA produced no serious adverse side effects. Some participants temporarily experienced mild symptoms like nausea and loss of appetite. Unlike traditional pharmaceuticals, MDMA does not act as a band-aid that tries to blunt symptoms of PTSD. Instead, in people with PTSD, MDMA combined with therapy seems to allow the brain to process painful memories and heal itself. Scott Ostrom, who participated in the study, had suffered from PTSD since returning home from his second deployment in Iraq in 2007. For more than a decade, he experienced debilitating nightmares. Mr. Ostrom's days were punctuated by panic attacks, and he dropped out of college. Therapy and medication did not help. But after participating in the trial, he no longer has nightmares. "Literally, I'm a different person," he said.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
There is clearly a psychedelic renaissance underway. These agents are now debated at medical conferences smirk-free, and my investment-obsessed friends predict a financial "â€shroom-boom". During the 2020 US election ... Measure 109 asked voters in Oregon whether magic mushrooms should be allowed for medical purposes, and Initiative 81 asked Washingtonians about decriminalizing psychedelic plants and fungi. Research is also underway in institutions from Johns Hopkins to Imperial College London. Recently, Health Canada quietly ... allowed four terminally ill patients to take psilocybin under medical supervision. I have also been asked by several patients, at end-of-life, to prescribe a gram of mushrooms or a tablet of lysergic acid diethylamine (which my pharmacy cannot furnish), rather than a "bucket of fentanyl" (which the pharmacy readily can). The Default Mode Network (DMN) ... refers to interconnected brain regions that help us believe we are a distinct self, separate from others and the natural world. This drives self-reliance, but can make us feel isolated. Moreover, as it "matures," we respond in more habitual, predictable, rigid ways. The theory is that DMN overactivity leads to excessive introspection, hypercriticism, obsession, depression, and anxiety. Psychedelics might decrease the tyranny of the DMN, thereby allowing unfamiliar parts of the brain to go on a play-date. We should not throw out the scientific method, but psychedelics could increase the colors in our crayon set.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
Gov. Kate Brown of Oregon announced the members of the state's newly formed Psilocybin Advisory Board this week. Oregon is about to become the first state in the country to try to build a support infrastructure through which psychedelic mushrooms can be woven into everyday life. This framework is different from what we've seen before: not legalization, not medicalization, but therapeutic use, in licensed facilities, under the guidance of professionals trained to guide psychedelic experiences. The ... pressing case for psilocybin comes from research out of Johns Hopkins, U.C.L.A., N.Y.U. and elsewhere that has shown it to be a potentially effective treatment for major depression, end-of-life anxiety and drug addiction. "One of the things I've come to is that addiction medicine in 2021 is in desperate need of transformative technologies," Todd Korthuis, a ... member of Oregon's Psilocybin Advisory Board, told me. Studies ... are "showing dramatic change in people's lives – that's what we need for cocaine use disorder, methamphetamine use disorder, even alcohol and tobacco." A recent study on major depressive disorder, published in JAMA Psychiatry, found more than half of the subjects in remission four weeks later, after just two treatments alongside psychotherapy. A study on tobacco addiction, out of Johns Hopkins, found two-thirds of the subjects who received psilocybin in combination with cognitive behavioral therapy abstinent a year later.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
In the summer of 1981, when he was 13, Grant crashed a trail motorbike. Grant hadn't given this childhood memory much thought in the intervening years, but one hot August day ... he suddenly understood it as a clue to his dangerously unhealthy relationship with alcohol. The day before, a team of specialists at the Royal Devon and Exeter hospital had given him an intravenous infusion of ketamine, a dissociative hallucinogen, in common use as an anaesthetic since the 1970s, and more recently one of a group of psychedelic drugs being hailed as a silver bullet in the fight to save our ailing mental health. To date, more than 100 patients with conditions as diverse as depression, PTSD and addiction have been treated in research settings across the UK, using a radical new intervention that combines psychedelic drugs with talking therapy. What was once a fringe research interest has become the foundation of a new kind of healthcare, one that, for the first time in modern psychiatric history, purports to not only treat but actually cure mental ill health. Under its influence, Grant had an out-of-body experience he struggles to put into words. "It was like I was sinking deeper and deeper into myself," he says. "Then I became white… and I left my body. I was up on the ceiling, looking at myself, but I was just this white entity. I felt very serene and humbled; I finally understood my place in the universe, just a white speck of light, I wasn't the centre of everything and that was fine."
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind altering drugs from reliable major media sources.
Massachusetts General Hospital wouldn't seem like a natural fit for a center devoted to mind-altering drugs. But this week, MGH launched the Center for the Neuroscience of Psychedelics to study the potential of psilocybin and other psychoactive drugs to treat conditions such as depression, addiction, trauma, and more. The new center at MGH signifies that the field of psychedelic therapy has arrived. Inspiration came from the search for ways to ease the misery of patients whose mental illness is resistant to traditional treatments. Psychedelics are known to facilitate "plasticity" in the brain, increasing its capacity for change, and [director Jerrold] Rosenbaum said his team wanted to understand how these agents "move the brain to change in a way that can address many of the most anguishing forms of human suffering." The MGH center combines the disciplines of psychiatry, brain imaging, genomic medicine, and chemical biology. Some of the initial work involving patients will use psilocybin and be directed at rumination – the stuck, repetitive thought patterns that underlie several conditions, from addiction to obsessive-compulsive disorder. The future of the center's research is boundless, since psychedelics' role in neuroplasticity and neuritogenesis – the ability to build new synapses – may be useful in palliative care with terminally ill patients as well as in combatting neurodegenerative diseases such as Parkinson's and Alzheimer's.
Note: This article is also available on this webpage. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
As of 2018, nearly one in eight Americans use antidepressants. Unfortunately, more than a third of patients are resistant to the mood-improving benefits of medicine's best antidepressant drugs. These people are not completely out of options. There are chemicals already out there that can restore their mood balance, and in some cases, even save their lives. Chemicals such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms) and dimethyltryptamine (DMT) are more accurately called "serotonergic psychedelics" among the neuroscience community. At the correct doses, psychedelics are well tolerated, producing only minor side effects such as transient fear, perception of illusions, nausea/vomiting or headaches. These fleeting side effects pale in comparison to the severity of commonly prescribed antidepressants, which include dangerous changes in heart rate and blood pressure, paradoxical increases in suicidality, and withdrawal symptoms. As far as outcomes go, psychedelics in combination with psychotherapy are remarkably efficient at treating depression. Compared to selective serotonin reuptake inhibitors, or SSRIs, the current gold standard in antidepressant medication, psychedelics have a faster effect on patients, sometimes effective with only a single therapy session. Psychedelics also have a longer-lasting effect than an SSRI regimen. A 2015 study ... demonstrated that past history of psychedelic use decreases the odds of suicidal thoughts or actions over the course of a lifetime.
Note: Read more about the healing potentials of psychedelic medicine. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.
While I was in anesthesia residency at the University of Southern California Hospital's Department of Anesthesiology from 2006 to 2009, I learned how to put people under for surgery using an anesthetic called ketamine. Afterwards, as I began work as an anesthesiologist at a hospital, I began hearing interesting things about the anesthetic. Researchers had begun testing it as a treatment for mental health conditions like anxiety, depression, and PTSD – and with encouraging results. It also has psychedelic properties, so people can gain insight into their lives and even have mystical experiences on it. One study found that it reduced symptoms of depression and anxiety in patients with severe depression, both immediately after it was administered and as well as a month down the line. Another found that it even provided relief from chronic pain that lasted for up to two weeks after treatment. In 2014, inspired by findings like these and conversations with psychiatrists who were beginning to incorporate ketamine into their practices, I founded the Ketamine Healing Clinic of Los Angeles. Over time, I've seen people undergo big changes in their lives because of their work with ketamine, including a few who left abusive relationships, grew their businesses, or pursued totally new ventures. Overall ... people typically come out of their infusions with a newfound will to live and increased clarity about their future. Some patients who came in with suicidal thoughts no longer have them at all.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on recreational drugs across the country. Oregon's Measure 109 will give legal access to psilocybin, the main active ingredient in "magic mushrooms," for mental health treatment in supervised settings. While some cities have moved to legalize and regulate access to the drug, Oregon will become the first state in the country to legalize it on a statewide basis. Supporters of the measure point to the medical benefits of the drug, which has been shown in some studies to benefit trauma survivors. Through Measure 110, which has captured more than 58% of the vote so far, Oregon would also decriminalize the possession of small amounts of some hard drugs, including heroin and LSD. Instead of criminal prosecution, people in possession would face a $100 fine, which can be waived if the person agrees to pursue treatment, according to the measure. Ronan Levy, the cofounder of Field Trip Health, a Toronto-based company that provides psychedelic-enhanced psychotherapy, said the ballot wins are "fantastic news" for what he called the psychedelic renaissance. Research is mounting that indicates the benefits of using psychedelic drugs to enhance therapy, Levy said, adding that ... the drug alone isn't necessarily helpful; it needs to be taken under supervision of trained personnel.
Note: Recent studies suggest psilocybin can be used to treat addiction and anxiety. For more along these lines, see concise summaries of deeply revealing news articles on the healing potential of mind-altering drugs from reliable major media sources.
A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy. The Multidisciplinary Association for Psychedelic Studies, a nonprofit advocating for psychedelic research since the 1980s, is conducting its last phase of clinical trials to research the efficacy of using MDMA-assisted psychotherapy for post-traumatic stress disorder. PTSD afflicts about eight million adults a year. MDMA is more commonly known as the main component of Ecstasy. Armed with the new funding, MAPS is aiming to finish the trials and seek approval from the Food and Drug Administration to commercialize the MDMA-assisted psychotherapy as soon as 2022. In 2017, the FDA designated MDMA as a breakthrough therapy for PTSD, meaning it would expedite review of the drug. MAPS said a recent interim analysis of its Phase 3 clinical trials ... showed a very high likelihood the therapy will be effective for treating PTSD. In phase 2 clinical trials, individuals with post-traumatic stress disorder received psychotherapy, some with the psychedelic drug MDMA. More of those who received the drug no longer received a PTSD diagnosis in the months after treatment, compared with those who received a placebo. Business leaders said their donations came from a personal connection to mental-health conditions. Among them is billionaire Bob Parsons, founder of GoDaddy and ... a Marine Corps Vietnam War veteran, who said he has continued to battle PTSD.
Note: To read the entire article free of charge, see this webpage. Note that as big Pharma won't make big profits from these therapies, they are not funding any of the major studies, while the nonprofit MAPS has stepped in to make this happen. And not mentioned in this article is that the results of these studies has been dramatic, with over 2/3 of patients showing no signs of PTSD a year after treatment. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Older Americans suffer disproportionately from chronic pain and its attendant ailments, anxiety, depression and insomnia. In the search for relief, they consume more pharmaceutical drugs than perhaps any comparable cohort on this planet. Psychedelic therapies to treat mental health conditions offer a radical departure from current pharmaceutical models. The psychedelic therapy modalities currently under investigation combine a limited number of treatment sessions with a psychedelic substance, sandwiched between intensive pre- and post-treatment therapy sessions. The ideal, and realistic, outcome from this course of treatment is not mere symptom control, but durable remission. Indeed, these studies are finding that, in clinically significant numbers, recipients of a single course of psychedelic therapy report the experience to be life-changing, and enduring over time. The positive preliminary outcomes of clinical studies by MAPS using MDMA to treat PTSD, and Compass Pathways for psilocybin therapy for treatment-resistant depression, have convinced the FDA to grant them Breakthrough Therapy Designation. In the 1960s researchers were interested in seeing if psychedelic drug treatment could alleviate existential distress in terminal cancer patients. This line of research was picked up 35 years later by Dr. Charles Grob, whose 2011 pilot study of psilocybin treatment for terminal cancer patients found significant enduring reductions in anxiety and improvement in mood at a six-month follow up.
Note: Read more on the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.